» Articles » PMID: 16186416

Hypercholesterolemia Abrogates Late Preconditioning Via a Tetrahydrobiopterin-dependent Mechanism in Conscious Rabbits

Overview
Journal Circulation
Date 2005 Sep 28
PMID 16186416
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the late phase of ischemic preconditioning (PC) is known to confer cardioprotection in healthy animal models, it is unknown whether this phenomenon exists in the presence of hypercholesterolemia. The goal of this study was to determine whether the infarct-sparing effect of late PC is affected by hypercholesterolemia and, if so, whether a tetrahydrobiopterin (BH4)-dependent mechanism is responsible for the loss of late PC.

Methods And Results: Conscious rabbits fed a normal diet or a 1% cholesterol diet for 6 weeks were subjected to ischemic PC (six 4-minute coronary occlusion/4-minute reperfusion cycles) and, 24 hours later, underwent a 30-minute occlusion followed by 3 days of reperfusion. A total of 125 rabbits were used. In normocholesterolemic rabbits, ischemic PC reduced infarct size, an effect that was abrogated by administration of the BH4 synthesis inhibitor N-acetylserotonin (15 mg/kg IV) before the 30-minute occlusion. In hypercholesterolemic rabbits, however, ischemic PC failed to reduce infarct size. Myocardial BH4 levels in the ischemic zone increased 24 hours after ischemic PC in normocholesterolemic rabbits but not in hypercholesterolemic rabbits. In addition, in normocholesterolemic rabbits, pretreatment with N-acetylserotonin completely abolished the ischemic PC-induced increase in myocardial BH4 levels.

Conclusions: This study demonstrates that (1) hypercholesterolemia abrogates both the infarct-sparing effect of late PC and the concomitant upregulation of myocardial BH4, and (2) inhibition of myocardial BH4 synthesis in the absence of hypercholesterolemia is sufficient to abolish the infarct-sparing effect of late PC. The results support the concept that hypercholesterolemia abrogates late PC by preventing the upregulation of BH4, an essential cofactor for inducible nitric oxide synthase.

Citing Articles

Hypercholesterolemia attenuates cardioprotection of ischemic preconditioning and postconditioning with α7 nicotinic acetylcholine receptor agonist by enhancing inflammation and inhibiting the PI3K/Akt/eNOS pathway.

Wen C, Xue F, Wang Y, Jin J, Liao X Exp Ther Med. 2022; 23(5):342.

PMID: 35401808 PMC: 8988135. DOI: 10.3892/etm.2022.11272.


Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection.

Billah M, Ridiandries A, Allahwala U, Mudaliar H, Dona A, Hunyor S Oncotarget. 2019; 10(2):216-244.

PMID: 30719216 PMC: 6349428. DOI: 10.18632/oncotarget.26537.


Ischemic preconditioning: Interruption of various disorders.

Goyal A, Agrawal N J Saudi Heart Assoc. 2017; 29(2):116-127.

PMID: 28373786 PMC: 5366670. DOI: 10.1016/j.jsha.2016.09.002.


Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Andreadou I, Iliodromitis E, Lazou A, Gorbe A, Giricz Z, Schulz R Br J Pharmacol. 2017; 174(12):1555-1569.

PMID: 28060997 PMC: 5446572. DOI: 10.1111/bph.13704.


Increased 12/15-Lipoxygenase Leads to Widespread Brain Injury Following Global Cerebral Ischemia.

Yigitkanli K, Zheng Y, Pekcec A, Lo E, van Leyen K Transl Stroke Res. 2016; 8(2):194-202.

PMID: 27838820 PMC: 5350054. DOI: 10.1007/s12975-016-0509-z.


References
1.
Patel K, Stratford M, Wardman P, Everett S . Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med. 2002; 32(3):203-11. DOI: 10.1016/s0891-5849(01)00777-8. View

2.
Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S . Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol. 2002; 22(10):1655-61. DOI: 10.1161/01.atv.0000029122.79665.d9. View

3.
Ferdinandy P . Myocardial ischaemia/reperfusion injury and preconditioning: effects of hypercholesterolaemia/hyperlipidaemia. Br J Pharmacol. 2003; 138(2):283-5. PMC: 1573675. DOI: 10.1038/sj.bjp.0705097. View

4.
Wang T, Chen W, Mau T, Lin J, Lin W, Lee Y . Attenuation of increased myocardial ischaemia-reperfusion injury conferred by hypercholesterolaemia through pharmacological inhibition of the caspase-1 cascade. Br J Pharmacol. 2003; 138(2):291-300. PMC: 1573676. DOI: 10.1038/sj.bjp.0705098. View

5.
Eto Y, Shimokawa H, Tanaka E, Morishige K, Fuchigami M, Ishiwata Y . Long-term treatment with propagermanium suppresses atherosclerosis in WHHL rabbits. J Cardiovasc Pharmacol. 2003; 41(2):171-7. DOI: 10.1097/00005344-200302000-00004. View